1×1 LTE tDCS Device

Limited Total Energy tDCS For Susceptible Subjects

The Soterix Medical 1×1-LTE is the only tDCS device optimized for susceptible populations with features optimized to reduce anxiety and sensation including SmartScan™, Relax™, and Tickle™. Additionally with an exclusive feature of Soterix Medical LTE™, makes it the most intelligent power and transient management system for currents up to 1.5 mA.

Limited Total Energy™ (LTE)

Limited Total Energy for tDCS (LTE-tDCS) was developed exclusively by Soterix engineers. LTE limits the voltage and power required for tDCS through the use of adaptive ramp-up stimulation and intelligent energy management for currents up to 1.5 mA. The Soterix Medical 1×1 tDCS-LTE includes the most advanced transient protection in the industry should an electrode become temporarily disconnected, for example due to subject movement. In addition, should resistance increase to atypical levels, LTE-tDCS will automatically reduce the applied current so as to maintain a low voltage.
"Soterix Medical tDCS-LTE is a unique system that provides an additional safety margin, without compromising efficacy, when stimulating susceptible subjects."

Our scientific team is ready to work with you to determine optimal dose parameters and accessories.

Request Product Information LTE-tDCS Manual & Specifications

Proven to Limit Power During tDCS

The difference between conventional tDCS and tDCS-LTE is that conventional tDCS applies a fixed ramp slope while tDCS-LTE varies ramp intensity to limit power delivery. Soterix tDCS-LTE also limits power transients that might occur during tDCS due to sudden changes in resistance. tDCS-LTE further enhances abort-protection features already enabled on all Soterix 1x1 devices. Finally, tDCS-LTE alerts the operator when a high-power condition occurs and automatically activates LTE to reduce power consumption.

Our scientific team is ready to work with you to determine optimal dose parameters and accessories.

Focus on the subject, not the device with

Open-Panel™ controls

The Soterix Medical Open-Panel™ control system was developed to allow simple dose setting in seconds. With easy-click control knobs to set stimulation duration and intensity, and back-lit status display visible even at a distance. SmartSCAN™ provides a constant indication of electrode quality and with Soterix Medical LTE™ automatically managing dose, allows you to focus on your subject from set-up, to stimulation, to ramp-down.

Device Features

Soterix Medical 1×1 features were optimized by our biomedical engineers consulting closely with leading TBI rehabilitation clinics and pediatric neurologists. Designed for simple set-up, provide intelligent warning of a fault condition, and allow for adjusting for patient comfort , these features facilitate reliable and tolerated tDCS. The Soterix Medical SmartScan™ feature is central in all Soterix tDCS devices to allow reliable set-up and monitoring. The Relax™, Tickle™, and TrueCurrent™ innovations were developed for the 1×1 tDCS platforms. Limited Total Energy (LTE™) is available exclusively on the ×-LTE platform.

Limited total energy provides adaptive ramp-up stimulation technology to limit the required voltage.

Advanced transient protection should an electrode become temporarily disconnected. LTE-tDCS will automatically reduce the applied current so as to maintain a low voltage should resistance increase to atypical levels.

Provides a continuous visual indication of electrode quality before and during stimulation.

From pre-stimulation set-up, to during stimulation monitoring, to post-stimulation confirmation, the Soterix Medical SmartScan™ feature provides an intuitive and clear indication of electrode contact quality. Use the SmartScan™ during set-up to adjust electrodes and head-gear for optimal fit. During stimulation, SmartScan™ provides a constant indication of electrode quality and can be monitored during adjustments (e.g. addition of saline to drying electrodes). After stimulation, SmartScan™ confirms a successful trial. Because “resistance” is not meaningful for tDCS, SmartScan™ was developed by Soterix Medical engineers to provide clinical investigators with a simple to read indication of contact quality.

Clearly indicates the actual current supplied at the moment.

What other devices promise, the 1×1 tDCS delivers. The back-lit display can be monitored during stimulation ramp up and to confirm target current intensity is achieved.

May be used to supply a very weak current prior to tDCS to help condition the skin.

Tickle™ may be used to both condition skin prior to tDCS and for naïve subject anxious about stimulation. A custom on-off waveform pattern generates mild and brief sensation under electrodes.

Allows the clinician to use a simple sliding bar to transiently decrease the current from the pre-set value, for example based on subject feedback.

Based on feed-back from leading clinical centers, Soterix Medical exclusive feature Relax™ accommodates subjects who may be anxious when stimulation is initiated or during the course of stimulation. The Relax™ slider may be adjusted from full to reduced intensity based on subject perception without interrupting or aborting stimulation.

Simple and intelligent sham waveforms.

An automatic stimulation sham feature that is engaged with a simple switch. Auto-sham automatically calculated and produces a sham waveform based on the the indicated “real” waveform. For example, for a corresponding real waveform of 1.5 mA and 10 minutes. auto-sham will provide a ramp up/down to 1.5 mA at the start of of stimulation, and again after 10 minutes, with the timer automatically adjusted such that the total run time us exactly matched to the real case. Based on the Soterix Medical OpenPanelTM design principle: with no complicated programming or hidden drop-down menus required.

Request Product Information LTE-tDCS Manual & Specifications

Dose Guidelines for Susceptible Subjects

In tDCS one size does not fit all, and nowhere is this more sensitive than in susceptible populations. Soterix Medical scientists are working with leading pediatric neurology clinical research centers to refine and optimize dose strategies. With access to Soterix Medical Solution services and Software, tDCS 1x1-LTE users are part of this community and dialogue.

Our scientific team is ready to work with you to determine optimal dose parameters and accessories.

tDCS Accessories

Every tDCS 1×1 accessory is optimized for simple and consistent set-up, robust and safe performance, and ease of use. "One size does not fit all" in tDCS, and the 1×1 accessory set provides the flexibility to optimize performance. For EasyPads™ to EasyStraps™ Soterix Medical 1×1 tDCS accessories are designed and validated specifically for the 1×1 platform. Our scientific team is ready to help you select the best accessory set to make your 1×1 the most targeted platform adjustable to any application.

Clinical Trials

tDCS and Talking Therapy for Aphasia

Hunter College of The City University of New York will investigate the use of Soterix Medical 1x1 tDCS (transcranial direct current stimulation) in conjunction with speech-language therapy, for the improvement of language production in stroke survivors with aphasia.

Phase III Clinical Trial for major depressive disorder

Trial will compare Soterix Medical tDCS-LTE™ technology against a fully dosed, effective antidepressant Escitalopram oxalate (Lexapro). Recruitment ongoing.
Soterix Medical 1×1 Clinical Trials (CT) device using Limited Total Energy (LTE™) technology is being used in the study.

Neuromodulation of cognition in older adults

Study investigates whether transcranial direct current stimulation enhances the effects of cognitive training in healthy older adults.
Soterix Medical 1×1 tDCS device is being used in this study.

Treatment of chronic pelvic pain assosicated with Endometriosis.

The purpose of this study is to determine if transcranial direct current stimulation (tDCS) is effective in the treatment of chronic pelvic pain associated with endometriosis
Soterix Medical 1×1 tDCS device is being used in this study.

Open Label Treatment With tDCS for Parkinson's and Related Disorders.

The purpose of this study is to determine if treatment with tDCS for Parkinson's and Related Disorders has any improvement of Speech, Gait and Mood.
Soterix Medical 1×1 CT device is being used in this study.

Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment

The main idea of this study is that brain stimulation can enhance functioning in the specific brain regions/networks, thereby increasing the patients' ability to benefit from memory rehabilitation.
Soterix Medical 1×1 CT device is being used in this study.

Refractory Epilepsy Trial

High-Definition tDCS (HD-tDCS) clinical trial underway for Treatment of Refractory Partial Onset Epilepsy in adults and children at NYU School of Medicine.
Soterix Medical HD-tDCS device is being used in this study.

Effects of tDCS on Motor Learning in Children With Cerebral Palsy (CP)

Trial will assess the clinical and neurophysiological effects of a non-invasive brain stimulation technique - transcranial direct current stimulation (tDCS)- on cortical plasticity and motor learning in children with cerebral palsy.

Cognitive Stimulation Study (CogStim)

This study will evaluate the influence of non-invasive brain stimulation on different elements of cognitive function in healthy persons between the ages of 18-90 years. Soterix Medical 1×1 tDCS device is being used in this study.

Neuropathic Symptoms Following Burn Injury Trial

Spaulding Rehabilitation Hospital and the US Department of Education will investigate the effects of Soterix Medical 1x1 transcranial direct current stimulation (tDCS) on the pain and itching associated with burn injury. This study is part of the Boston-Harvard Burn Model System.

Phase II Fibromyalgia Trial

Follow up Phase II, HD-tDCS clinical trial underway for fibromyalgia at Harvard Medical School and Spaulding Rehabilitation Hospital, and in conjunction with Elminda Corporation. Exclusive Soterix 4x1 HD-tDCS being used.

Abdominal pain in patients with chronic pancreatitis Clinical Trial

This study is testing whether the addition Soterix Medical 1x1 transcranial direct current stimulation (tDCS) when combined with meditation helps decrease the abdominal pain in patients with chronic pancreatitis.

Corneal Pain Clinical Trial

Study focused on investigating effect of tDCS on chronic corneal pain as well as changes in thought processing as compared to healthy controls. Soterix 1×1 Device is being used.

Stroke Recovery Clinical Trial

Study focused on evaluating the effect of a combination of robotic arm therapy and transcranial Direct Current Stimulation for greater functional recovery after stroke.

Depression Clinical Trial

For the most comprehensive tDCS trial to-date, researchers selected the most advanced tDCS device and the only system optimized for clinical trials – The Soterix Medical 1x1-CT.

Pediatric Epilepsy Trial

Epilepsy Foundation awards a New Therapy Grant for a clinical trial of High-Definition tDCS in pediatric epilepsy. Dr. Alexander Rotenberg will lead a team of clinical investigators including at BCH and Harvard Medical School.

Stroke Rehabilitation Trial

NIH grants Burke Medical Research Institute $3m to conduct the most controlled trial of tDCS for stroke rehabilitation to date. The Soterix Medical 1x1 platform is the most advanced and the industry standard for tDCS clinical trials for rehabilitation.

Down Syndrome Trial

Soterix Medical Inc. receives FDA Clinical Trial IDE for High-Definition tDCS (HD-tDCS) to improve IQ in pediatric Down syndrome. HD-tDCS is the only non-invasive, brain targeted, and low-intensity technology designed to promote neuroplasticity.

Pediatric Hemiparesis Trial

Dr. Bernadette Gillick's Pediatric Rehabilitation Laboratory is supported by the NIH and University of Minnesota Clinical and Translational Science Institute to investigate the use of a form of tDCS for interventions in rehabilitation for children. Subject specific analysis with Soterix Medical Neurotargeting™ will guide current to brain cells in the injured part of the brain.

Fibromyalgia Clinical Trial

HD-tDCS clinical trial underway for fibromyalgia at Harvard Medical School and Spaulding Rehabilitation Hospital, Boston.

Stroke Rehabilitation Clinical Trial

NIH grants Soterix a Phase-1 STTR grant to develop HD-tDCS for stroke rehabilitation. The first technology capable of delivering therapeutic direct current to target brain regions involved in functional recovery.

tDCS Software

Optimization of electrode montage for brain targeting and individual subject customization has never been as easier as with Soterix Medical's Neurotargeting software. With recognition that placing an electrode "over" a target does not support rational tDCS does design, the Soterix Medical Suite of software tools allow simple and automatic optimization. Soterix Neurotargeting software also provides high-resolution current flow visualization that can be used to support publications, presentation and proposals.

Caution! Investigational Device. Federal (or United States) law limits device to investigational use.